Neurology is experiencing a resurgence, highlighted by increased deal activity, clinical advancements and a notable IPO. This revival, though less conspicuous than obesity’s, emerges from years of underinvestment, resulting in a landscape filled with unmet needs and appealing commercial prospects amid scant competition.
There’s plenty to go after: the neurology arena encompasses widespread degenerative conditions like Alzheimer’s or Parkinson’s, as well as epilepsy, depression, migraine, pain and multiple rare diseases.
In this eBook, Evaluate provides a snapshot of some of the most interesting players in the field, looking at their pipeline highlights, marketed drugs and what makes them ones to watch.
HIGHLIGHTS
- The Alzheimer’s landscape opens up
- Past failures are resurrected
- Street drugs are medicalised
- Promising molecules and mechanisms emerge
